Trial Outcomes & Findings for Gut Organoid and Microbiome Interactions in Hypertension (NCT NCT04497727)

NCT ID: NCT04497727

Last Updated: 2025-09-29

Results Overview

Number of differentially expressed genes identified through RNA sequencing of colonic epithelial tissue obtained during colonoscopy. Expression profiles were compared between individuals with High Blood pressure (HBP) (hypertensive group) and normotensive reference (REF) participants. Genes were considered differentially expressed if they met criteria of false discovery rate (FDR)-adjusted p-value \< 0.05 and absolute fold change ≥ 1.5.

Recruitment status

COMPLETED

Target enrollment

35 participants

Primary outcome timeframe

At time of colonoscopy (single visit)

Results posted on

2025-09-29

Participant Flow

Participant milestones

Participant milestones
Measure
Hypertensive Group
Participants were adults undergoing routine screening colonoscopy who met study eligibility criteria and provided written informed consent. Based on their blood pressure status, participants were categorized as individuals with high blood pressure (hypertensive group), defined according to the 2017 ACC/AHA guidelines
Normotensive Group
Participants were adults undergoing routine screening colonoscopy who met study eligibility criteria and provided written informed consent. Based on their blood pressure status, participants were categorized as individuals without hypertension (normotensive group) defined according to the 2017 ACC/AHA guidelines Gene Expression: Gene expression analysis of biopsy specimens obtained during routine colonoscopy examination
Overall Study
STARTED
16
19
Overall Study
COMPLETED
16
19
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Gut Organoid and Microbiome Interactions in Hypertension

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Hypertensive Group
n=16 Participants
Participants were adults undergoing routine screening colonoscopy who met study eligibility criteria and provided written informed consent. Based on their blood pressure status, participants were categorized as individuals with high blood pressure (hypertensive group), defined according to the 2017 ACC/AHA guidelines Gene Expression: Gene expression analysis of biopsy specimens obtained during routine colonoscopy examination
Normotensive Group
n=19 Participants
Participants were adults undergoing routine screening colonoscopy who met study eligibility criteria and provided written informed consent. Based on their blood pressure status, participants were categorized as individuals without hypertension (normotensive group), defined according to the 2017 ACC/AHA guidelines
Total
n=35 Participants
Total of all reporting groups
Age, Continuous
62 Years
n=99 Participants
55 Years
n=107 Participants
58 Years
n=206 Participants
Sex: Female, Male
Female
10 Participants
n=99 Participants
15 Participants
n=107 Participants
25 Participants
n=206 Participants
Sex: Female, Male
Male
6 Participants
n=99 Participants
4 Participants
n=107 Participants
10 Participants
n=206 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Asian
0 Participants
n=99 Participants
2 Participants
n=107 Participants
2 Participants
n=206 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Black or African American
4 Participants
n=99 Participants
2 Participants
n=107 Participants
6 Participants
n=206 Participants
Race (NIH/OMB)
White
11 Participants
n=99 Participants
13 Participants
n=107 Participants
24 Participants
n=206 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Unknown or Not Reported
1 Participants
n=99 Participants
2 Participants
n=107 Participants
3 Participants
n=206 Participants
Region of Enrollment
United States
16 Participants
n=99 Participants
19 Participants
n=107 Participants
35 Participants
n=206 Participants

PRIMARY outcome

Timeframe: At time of colonoscopy (single visit)

Population: Colonic biopsies from HBP participants revealed 35 differentially expressed genes (29 upregulated, 6 downregulated) compared to normotensive subjects (reference group).

Number of differentially expressed genes identified through RNA sequencing of colonic epithelial tissue obtained during colonoscopy. Expression profiles were compared between individuals with High Blood pressure (HBP) (hypertensive group) and normotensive reference (REF) participants. Genes were considered differentially expressed if they met criteria of false discovery rate (FDR)-adjusted p-value \< 0.05 and absolute fold change ≥ 1.5.

Outcome measures

Outcome measures
Measure
All Study Participants
n=35 Participants
Participants were adults undergoing routine screening colonoscopy who met study eligibility criteria and provided written informed consent.
Differential Gene Expression in Gut Epithelium
Upregulated Genes
29 Differentially expressed gene
Differential Gene Expression in Gut Epithelium
Downregulated Genes
6 Differentially expressed gene

PRIMARY outcome

Timeframe: Within days to weeks post-biopsy (in vitro culture period)

Population: No data obtained for this outcome measure because organoid preparations did not meet feasibility criteria for sample quantity and quality required for FACS and IHC. Further samples will never be obtained.

To compare growth rates and proportions of gut organoids derived from High Blood pressure (HBP) vs. normotensive (REF) participants.

Outcome measures

Outcome data not reported

Adverse Events

Hypertensive Group

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Normotensive Group

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Carl J. Pepine

University of Florida

Phone: (352) 339-0696

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place